MarkWide Research

Sale!

Nonalcoholic Steatohepatitis Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: July, 2022
No of Pages: 171
Delivery Format: PDF+ Excel

$2,950.00

High Demand for Noninvasive NASH Treatment to Augment Market

In the last couple of decades, the amount of diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD) cases has multiplied. The range of NAFLD stretches from steatosis to non-alcoholic-steatosis (NASH). The rising incidence of NAFLD has triggered a high cost in terms of burden to nations worldwide. As per the current trends, those with NAFLD-related illnesses are now among the main subset of people who require liver transplants. One of the primary reasons that could drive the adoption of NASH biomarkers is the high prevalence of NAFLD and its negative consequences. Traditional methods for treating NAFLD like a biopsy are declining steadily because of limitations, such as sampling errors, complications like bleeding, pain, mortality, and low acceptance.

The need for noninvasive methods for treating NAFLD has experienced steady growth in the past ten years. Noninvasive techniques that are gaining a lot of attention to fight NAFLD comprise NASH, NAFLD-related fibrosis, and steatosis, among others. The popularity of these noninvasive treatments is predicted to increase market demand for NASH biomarkers in the coming timeframe. Recently, the players who operate in the global market for NASH biomarkers have been increasingly examining the strategies that use non-imaging and imaging biomarkers that can identify fibrosis and limit biopsies in clinical situations. Technology advances, research and development efforts, and the high incidence of NAFLD are a few of the main factors likely to propel the market growth for the non-alcoholic steatohepatitis (NASH) marketplace for biomarkers at the time of assessment. Due to these elements, the non-alcoholic steatohepatitis (NASH) market for biomarkers is anticipated to grow to a market size of US$ 2 billion by the close of 2027.

Adoption of NASH Biomarkers to Address Idiopathic Pulmonary Fibrosis

Innovations in the healthcare industry and research initiatives will be a significant factor in expanding the sector of non-alcoholic steatohepatitis (NASH) markets for biomarkers. In recent years, a considerable amount of study has been conducted to discover the possible treatments for Idiopathic Pulmonary Fibrosis(IPF). In the last ten years, the progression between NAFLD and NASH has rapidly increased. It has become among the top widespread chronic liver disorders, especially in Western regions, including North America and Europe. It is believed that the generation of NASH biomarkers is predicted to increase significantly.

Presently, researchers are increasingly focused on improving the effectiveness of NASH biomarkers, healthcare professionals medical professionals; healthcare professionals are predicted to raise awareness about NASH. Medical experts believe that the incidence of NASH is expected to increase quickly in the next decade, so effective strategies are needed to fight the same. Public health organizations and government agencies, especially in the developed regions, are working on drafting new guidelines to govern the treatment of NASH. The latest developments in the non-alcoholic steatohepatitis (NASH) market for biomarkers tend to focus on advancements in noninvasive screening and diagnostic tests. Additionally, the companies operating in the market are increasingly looking at different drugs to treat NASH. In addition, a lot of drugs are currently in phase 3 trials, and a variety of drugs are being developed across the globe. Companies operating in the current market tend to focus on replacing painful, intrusive biopsies using noninvasive NASH biomarkers. The new project from the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium aims to make standardized biological markers for diagnostics of NASH. The Noninvasive Metabolic Biomarkers of Liver Project is expected to conduct an explicit comparison of conventional and non-conventional approaches to combat NASH and recommend the most effective methods to detect NASH. The projects will increase the commercialization of NASH biomarkers in the forecast period and consequently will boost the growth of the market for non-alcoholic steatohepatitis (NASH) markets for biomarkers.

Companies Adapt, Adjust, and Assess Pipeline Products, Seek FDA Approval

The development of the novel coronavirus pandemic is anticipated to create significant obstacles for businesses operating in the present market for the non-alcoholic steatohepatitis (NASH) market for biomarkers. The mobilization of researchers, frontline manufacturers, clinicians, and other stakeholders within the value chain has become a key area of concern amid the chaos. In the wake of the economic and health crisis all over the world Global Liver Institute, Global Liver Institute recently disclosed its plans to tackle the global pandemic by adapting and offering creative solutions. Although supply chains in the market for non-alcoholic steatohepatitis (NASH) marketplace for biomarkers are expected to be disrupted by the virus, businesses must implement efficient business continuity strategies and diversify their product lines to meet the challenges that are posed by the pandemic’s global reach.

Analysts Viewpoint

The NASH (NASH) biomarkers industry is projected to grow by a staggering CAGR of 21% over the forecast time. This market growth could be explained by a range of reasons, such as the high demand for noninvasive strategies to combat NASH research and development initiatives, government support for creating NASH biomarkers, and the high concentration on reducing the incidence of NAFLD and diabetes. Market players will likely focus on developing novel NASH biomarkers and obtaining approval from the FDA. Furthermore, North America and Europe will probably be the most active areas of development in the global non-alcoholic steatohepatitis (NASH) markets for biomarkers.

Nash Biomarkers Market Report Scope and Segmentation

ATTRIBUTESDETAILS
ESTIMATED YEAR2022
BASE YEAR2021
FORECAST YEAR2030
HISTORICAL YEAR2017-2021
UNITValue (USD Million/Billion)
BY REGIONNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Overview

  • The market for non-alcoholic steatohepatitis (NASH) biomarkers market estimated at US$300 million in 2018. and is expected to increase between 2020to and 2027. The rise of NAFLD as well as NASH conditions; rise in patients who suffer from obesity and metabolic diseases; increase in the geriatric population; increase in the prevalence of Type II diabetes, prediabetes, and Type adult patients; increase in demand for noninvasive diagnostic tools and increased awareness of NASH conditions and the latest diagnostic techniques, especially in the developing markets. These are expected to boost the market for non-alcoholic steatohepatitis (NASH) and the need for biomarkers.
  • NASH, also referred to as non-alcoholic-steatohepatitis, is a progressive type of non-alcoholic fatty liver disease(NAFLD). NAFLD is a disorder where fat accumulates in the liver. The continual deposition of fat can cause liver inflammation and cell damage. This is known to be a NASH condition. The rise in the prevalence worldwide of obesity and type 2 diabetes, metabolic diseases, and prediabetes are the primary reasons for the increased incidence of non-alcoholic steatohepatitis. This is why new diagnostic tools are now available to identify non-alcoholic steatohepatitis disorder. Liver biopsy is among the tools used to determine the presence of NASH conditions. But, because of the costs associated with this procedure, several companies have started introducing biomarkers to aid in the diagnosis to help NASH patients. Various noninvasive biomarkers are available to detect the NASH disease, including biomarker panels, serum biomarkers, and fibrosis biomarkers. They also include imaging biomarkers and gene biomarkers markers for oxidative stress and Cytokeratin-18.
  • As per research, the worldwide prevalence of NASH is estimated to be in a range of1.5%6.45%, respectively, in 2019.NASH prevalence across the globe is expected to grow by63%by2030. Numerous biotech and pharmaceutical firms are investing money in developing treatments for NASH. Presently, 95 potential drugs from different companies are in the pipeline, ranging from preclinical trials to trial stages 3. They will need NASH biomarker diagnostics to track and assess the effectiveness of drugs during clinical trials. Numerous 
  • Type Outlook (Revenue, USD Million, 2014 – 2028)
    • Serum biomarkers
    • Hepatic fibrosis biomarkers
    • Apoptosis biomarkers
    • Oxidative stress biomarkers
    • Others
  • End-use Outlook (Revenue, USD Million, 2014 – 2028)
    • Pharma & CRO Industry
    • Hospitals
    • Diagnostic Labs
    • Academic Research Institutes

COMPETITIVE OUTLOOK

The prominent companies engaged in the non-alcoholic steatohepatitis (NASH) biomarker include Allergan, Merck & Co, Novartis AG, Viking Therapeutics, Bristol Myers Squibb Company, Novo Nordisk, Genfit SA, Pfizer Inc, Madrigal Pharmaceuticals, Gilead Sciences Inc, AstraZeneca, Zydus Cadila, and Siemens Healthineers.

By Region

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Italy
    • France
    • UK
    • Spain
    • Poland
    • Russia
    • The Netherlands
    • Norway
    • Czech Republic
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Indonesia
    • Malaysia
    • Thailand
    • Singapore
    • Australia & New Zealand
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Rest of South America
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Northern Africa
    • Rest of MEA

Table of Contents

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Non-alcoholic Steatohepatitis Biomarkers Market

4. Market Overview

4.1. Introduction

4.1.1. Market Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast, 20172027

4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Disease Prevalence & Incidence Rate globally with Key countries

5.2. Regulatory Scenario by Region/globally

5.3. Pipeline Analysis

6. Global Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast, by Biomarker Type

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 20172027

6.3.1. Serum Biomarkers

6.3.1.1. Cytokeratin-18 (CK 18) Marker

6.3.1.2. Inflammatory markers

6.3.1.3. Others

6.3.2. Biomarker Panel

6.3.3. Fibrosis Biomarkers

6.3.4. Imaging Biomarkers

6.3.5. Others

6.4. Market Attractiveness Analysis, by Biomarker Type

7. Global Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast, by End-user

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 20172027

7.3.1. Hospitals

7.3.2. Diagnostic Centers

7.3.3. Others

7.4. Market Attractiveness Analysis, by End-user

8. Global Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast, by Region

8.1. Key Findings

8.2. Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Region

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Latin America

8.2.5. Middle East & Africa

8.3. Market Attractiveness Analysis, by Region

9. North America Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast

9.1. Introduction

9.1.1. Key Findings

9.2. North America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 20172027

9.2.1. Serum Biomarkers

9.2.1.1. Cytokeratin-18 (CK 18) Marker

9.2.1.2. Inflammatory Markers

9.2.1.3. Others

9.2.2. Biomarker Panel

9.2.3. Fibrosis Biomarkers

9.2.4. Imaging Biomarkers

9.2.5. Others

9.3. North America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 20172027

9.3.1. Hospitals

9.3.2. Diagnostic Centers

9.3.3. Others

9.4. North America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Country, 20172027

9.4.1. U.S.

9.4.2. Canada

9.5. North America Non-alcoholic Steatohepatitis Biomarkers Market Attractiveness Analysis

9.5.1. By Biomarker Type

9.5.2. By End-user

9.5.3. By Country

10. Europe Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. Europe Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 20172027

10.2.1. Serum Biomarkers

10.2.1.1. Cytokeratin-18 (CK 18) Marker

10.2.1.2. Inflammatory Markers

10.2.1.3. Others

10.2.2. Biomarker Panel

10.2.3. Fibrosis Biomarkers

10.2.4. Imaging Biomarkers

10.2.5. Others

10.3. Europe Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 20172027

10.3.1. Hospitals

10.3.2. Diagnostic Centers

10.3.3. Others

10.4. Europe Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Country/Sub-region, 20172027

10.4.1. Germany

10.4.2. U.K.

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Rest of Europe

10.5. Europe Non-alcoholic Steatohepatitis Biomarkers Market Attractiveness Analysis

10.5.1. By Biomarker Type

10.5.2. By End-user

10.5.3. By Country/Sub-region

11. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 20172027

11.2.1. Serum Biomarkers

11.2.1.1. Cytokeratin-18 (CK 18) Marker

11.2.1.2. Inflammatory Markers

11.2.1.3. Others

11.2.2. Biomarker Panel

11.2.3. Fibrosis Biomarkers

11.2.4. Imaging Biomarkers

11.2.5. Others

11.3. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 20172027

11.3.1. Hospitals

11.3.2. Diagnostic Centers

11.3.3. Others

11.4. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Country/Sub-region, 20172027

11.4.1. China

11.4.2. Japan

11.4.3. India

11.4.4. Australia & New Zealand

11.4.5. Rest of Asia Pacific

11.5. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Attractiveness Analysis

11.5.1. By Biomarker Type

11.5.2. By End-user

11.5.3. By Country/Sub-region

12. Latin America Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Latin America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 20172027

12.2.1. Serum Biomarkers

12.2.1.1. Cytokeratin-18 (CK 18) Marker

12.2.1.2. Inflammatory Markers

12.2.1.3. Others

12.2.2. Biomarker Panel

12.2.3. Fibrosis Biomarkers

12.2.4. Imaging Biomarkers

12.2.5. Others

12.3. Latin America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 20172027

12.3.1. Hospitals

12.3.2. Diagnostic Centers

12.3.3. Others

12.4. Latin America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Country/Sub-region, 20172027

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America

12.5. Latin America Non-alcoholic Steatohepatitis Biomarkers Market Attractiveness Analysis

12.5.1. By Biomarker Type

12.5.2. By End-user

12.5.3. By Country/Sub-region

13. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 20172027

13.2.1. Serum Biomarkers

13.2.1.1. Cytokeratin-18 (CK 18) Marker

13.2.1.2. Inflammatory Markers

13.2.1.3. Others

13.2.2. Biomarker Panel

13.2.3. Fibrosis Biomarkers

13.2.4. Imaging Biomarkers

13.2.5. Others

13.3. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 20172027

13.3.1. Hospitals

13.3.2. Diagnostics Centers

13.3.3. Others

13.4. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Country/Sub-region, 20172027

13.4.1. GCC Countries

13.4.2. South Africa

13.4.3. Rest of Middle East & Africa

13.5. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Attractiveness Analysis

13.5.1. By Biomarker Type

13.5.2. By End-user

13.5.3. By Country/Sub-region

14. Competitive Landscape

14.1. Market Share Analysis, by Company, 2018

14.2. Company Profiles

14.2.1.Biopredictive

14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.1.2. Product Portfolio

14.2.1.3. Strategic Overview

14.2.1.4. SWOT Analysis

14.2.2.Quest Diagnostics

14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.2.2. Financial Overview

14.2.2.3. Product Portfolio

14.2.2.4. Strategic Overview

14.2.2.5. SWOT Analysis

14.2.3.Exalenz Bioscience Ltd

14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.3.2. Financial Overview

14.2.3.3. Product Portfolio

14.2.3.4. Strategic Overview

14.2.3.5. SWOT Analysis

14.2.4.GENFIT

14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.4.2. Financial Overview

14.2.4.3. Product Portfolio

14.2.4.4. Strategic Overview

14.2.4.5. SWOT Analysis

14.2.5.Siemens Healthineers

14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.5.2. Financial Overview

14.2.5.3. Product Portfolio

14.2.5.4. Strategic Overview

14.2.5.5. SWOT Analysis

14.2.6.ONE WAY LIVER, S.L

14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.6.2. Product Portfolio

14.2.6.3. Strategic Overview

14.2.6.4. SWOT Analysis

14.2.7. Prometheus Laboratories Inc.

14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.7.2. Product Portfolio

14.2.7.3. Strategic Overview

14.2.7.4. SWOT Analysis

14.2.8.Gilead Sciences Ltd.

14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

14.2.8.2. Financial Overview

14.2.8.3. Product Portfolio

14.2.8.4. Strategic Overview

14.2.8.5. SWOT Analysis

List of Tables

Table 01: Opportunity Map, by Biomarker Type, 2018

Table 03: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Biomarker Type, 20172027

Table 04: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Serum Biomarker Type, 20172027

Table 05: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 20172027

Table 06: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Region, 20172027

Table 07: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Biomarker Type, 20172027

Table 08: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Serum Biomarker Type, 20172027

Table 09: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 20172027

Table 10: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Country, 20172027

Table 11: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Biomarker Type, 20172027

Table 12: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Serum Biomarker Type, 20172027

Table 13: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 20172027

Table 14: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 20172027

Table 15: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Biomarker Type, 20172027

Table 16: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Serum Biomarker Type, 20172027

Table 17: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 20172027

Table 18: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 20172027

Table 19: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Biomarker Type, 20172027

Table 20: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Serum Biomarker Type, 20172027

Table 21: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 20172027

Table 22: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 20172027

Table 23: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Biomarker Type, 20172027

Table 24: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Serum Biomarker Type, 20172027

Table 25: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 20172027

Table 26: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 20172027

List of Figures

Figure 01: Global Non-alcoholic Steatohepatitis Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027

Figure 02: Market Share Analysis, by Region, 2018

Figure 03: Global Non-alcoholic Steatohepatitis Biomarker Market Revenue Projection (US$ Mn), 20172027

Figure 04 : Market Value Share, by Biomarker Type, 2018

Figure 05: Market Value Share, by End-user, 2018

Figure 06: Market Value Share, by Region, 2018

Figure 07: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Biomarker Type, 2018 and 2027

Figure 08: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Biomarker Type, 20192027

Figure 09: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Serum Biomarkers, 20172027

Figure 10: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biomarker Panel, 20172027

Figure 11: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Fibrosis Biomarkers, 20172027

Figure 12: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Imaging Biomarkers , 20172027

Figure 13: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 20172027

Figure 14: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by End-user, 2018 and 2027

Figure 15: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by End-user, 20192027

Figure 16: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 20192027

Figure 17: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diagnostic Centers, 20192027

Figure 18: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 20192027

Figure 19: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Region, 2018 and 2027

Figure 20: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Region, 20192027

Figure 21: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 20192027

Figure 22: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Biomarker Type, 2018 and 2027

Figure 23: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Biomarker Type, 20192027

Figure 24: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by End-user, 2018 and 2027

Figure 25: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by End-user, 20192027

Figure 26: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Country, 2018 and 2027

Figure 27: North America Non-alcoholic Steatohepatitis ( NASH) Biomarkers Market Attractiveness, by Country, 20192027

Figure 28: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 20192027

Figure 29: Europe Non-alcoholic Steatohepatitis ( NASH) Biomarkers Market Value Share, by Biomarker Type, 2018 and 2027

Figure 30: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Biomarker Type, 20192027

Figure 31: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by End-user, 2018 and 2027

Figure 32: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by End-user, 20192027

Figure 33: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 34: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Country/Sub-region, 20192027

Figure 35: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 20192027

Figure 36: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Biomarker Type, 2018 and 2027

Figure 37: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Biomarker Type, 20192027

Figure 38: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by End-user, 2018 and 2027

Figure 39: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by End-user, 20192027

Figure 40: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 41: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Country/Sub-region, 20192027

Figure 42: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 20192027

Figure 43: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Biomarker Type, 2018 and 2027

Figure 44: Latin Ame

Major Companies

  • Biopredictive
  • Quest Diagnostics
  • Exalenz Bioscience Ltd
  • GENFIT
  • Siemens Healthineers
  • ONE WAY LIVER
  • S.L
  • Prometheus Laboratories Inc
  • Gilead Sciences Ltd.
  • Others

Segmentation

  • Type Outlook 
    • Serum biomarkers
    • Hepatic fibrosis biomarkers
    • Apoptosis biomarkers
    • Oxidative stress biomarkers
    • Others
  • End-use Outlook 
    • Pharma & CRO Industry
    • Hospitals
    • Diagnostic Labs
    • Academic Research Institutes

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF